Сблъскахте ли се " челно " с коронавируса? - Тема 2

CDC Warning: RSV cases and hospitalizations rising
Increased Respiratory Syncytial Virus (RSV) Activity in Parts of the Southeastern United States: New Prevention Tools Available to Protect Patients

Summary
The Centers for Disease Control and Prevention (CDC) issued a health alert via the Health Alert Network (HAN) Health Advisory to notify clinicians and caregivers about increases in respiratory syncytial virus (RSV) activity across some parts of the Southeastern United States in recent weeks, suggesting a continued shift toward seasonal RSV trends observed prior to the COVID-19 pandemic. Historically, such regional increases have predicted the beginning of RSV season nationally, with increased RSV activity spreading north and west over the following 2-3 months. RSV can cause severe disease in infants, young children, and older adults.

In anticipation of the onset of the 2023-2024 RSV season, CDC encourages clinicians to prepare to implement new RSV prevention options. Monoclonal antibody products, including a new, long-acting product, nirsevimab (BeyfortusTM, Sanofi and AstraZeneca), are available to protect infants and some young children at higher risk for severe RSV disease. For all infants ages <8 months, and infants and children ages 8-19 months who are at increased risk of severe RSV, clinicians should start to offer nirsevimab when it becomes available (expected by early October).

Also, two new vaccines are available to protect older adults from severe RSV disease. For adults ages 60 years and older, clinicians should offer a single dose of an RSV vaccine, either RSVPreF3 (Arexvy, GSK) or RSVpreF (AbrysvoTM, Pfizer), based on shared clinical decision-making between the healthcare provider and the patient. Clinicians should also talk to their patients about other vaccines available this fall to help prevent respiratory infections. Clinicians should consider testing symptomatic patients with high-risk conditions for COVID-19, influenza, and RSV to inform treatment decisions. Healthcare personnel, childcare providers, and staff at long-term care facilities should stay home and not go to work when they have fever or symptoms of respiratory infection to reduce the spread of respiratory infections including RSV.

Background
RSV is an RNA virus, and transmission occurs primarily via respiratory droplets when a person coughs or sneezes, or through direct contact with a contaminated surface. Infants, young children, and older adults, especially those with chronic medical conditions, are at increased risk of severe disease from RSV infection. CDC estimates that every year RSV causes approximately 58,000-80,000 hospitalizations (1,2) and 100-300 deaths (3,4) in children ages <5 years, as well as 60,000-160,000 hospitalizations (5,6) and 6,000-10,000 deaths (3,4,7) among adults ages 65 years and older.

In the United States, the annual RSV season has historically started in the fall and peaked in winter. However, this pattern was disrupted during the COVID-19 pandemic, likely due to public health measures to reduce the spread of COVID-19 that also reduced the spread of RSV. RSV activity was limited between May 2020 and March 2021, followed by an atypical season with onset in May 2021 that peaked in July and August and continued through the end of 2021 (. In 2022, RSV activity began in the summer, peaking across the United States in October and November, and rapidly declining by winter. Despite the disruptions in timing, RSV activity continued its geographic pattern of starting in Florida and the southeast before spreading to northern and western parts of the continental United States in 2021 and 2022.

In recent weeks, CDC has observed an increase in RSV activity in parts of the Southeastern United States. Nationally, the weekly percentage of positive detections reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS), a national laboratory-based surveillance network, has remained below the season onset threshold of polymerase chain reaction (PCR) test positivity of 3.0% for 2 consecutive weeks. However, NREVSS data show increases in weekly PCR positivity above 3.0% in Florida beginning in the week ending July 22, 2023, and the 3-week moving average of PCR positivity has been greater than 5.0% for the past 4 weeks. More robust data are available through Florida's sentinel surveillance, which also shows PCR positivity just under 5.0% for the most recent week. In Georgia, CDC has also observed an increase in rates of RSV-associated hospitalizations reported to RSV-NET, a population-based surveillance system. Among children ages <4 years, RSV-associated hospitalization rates increased from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population for the week ending August 19, 2023, with the majority occurring among infants ages <1 year. Due to reporting delays, surveillance data may be less complete in the 2 most recent weeks.

In 2023, new prevention tools for RSV have become available.

Nirsevimab is a long-acting monoclonal antibody approved by the Food and Drug Administration (FDA) to protect infants and some young children at increased risk for severe RSV disease. Nirsevimab is safe and efficacious. In clinical trials, one dose of nirsevimab administered as an intramuscular injection protected infants for at least 5 months (the length of an average RSV season) and reduced the risk of severe RSV disease by about 80% (9). The incidence of serious adverse events was not increased among nirsevimab recipients compared with placebo recipients in the clinical trials (9).
RSVPreF3 and RSVpreF are recombinant protein vaccines that are both approved by FDA for use in adults ages 60 years and older to prevent RSV-associated lower respiratory tract disease. During the first RSV season after vaccination, each vaccine was more than 80% efficacious in preventing RSV-associated lower respiratory tract disease (10). A small number of participants in clinical trials (6 of 38,177 total participants aged ≥60 years who received either vaccine) developed inflammatory neurologic events within 6 weeks after RSV vaccination, but it was unclear whether these events were related to RSV vaccination (10).
On August 21, 2023, FDA approved the RSVpreF vaccine (AbrysvoTM, Pfizer) for use in pregnant people during weeks 32 through 36 of gestation for the prevention of RSV-associated lower respiratory tract disease in infants from birth through 6 months of age. CDC's Advisory Committee on Immunization Practices (ACIP) will consider the evidence for a policy recommendation about RSV vaccination in this population in the future. CDC and FDA will continue to monitor the safety and effectiveness of RSV vaccines and nirsevimab, review data as collected, keep the public informed of findings, and use data to make recommendations - consistent with standard practices for all immunization products.

Recommendations for the Public

RSV vaccines for older adults: CDC recommends that adults ages 60 years and older may receive a single dose of RSV vaccine (either product) using shared clinical decision-making to prevent RSV-associated lower respiratory tract disease.

Expectant parents, parents of infants under the age of 8 months, and parents with older babies (through age 19 months) at increased risk of severe RSV disease should talk with their healthcare providers about using monoclonal (preventive) antibodies to protect against RSV this season. Infants under the age of 8 months should receive preventive antibodies to protect against RSV this season.

Adults ages 60 years and older should talk to their healthcare provider about whether RSV vaccination is appropriate for them.

Stay home and away from others when you are sick. If you are at increased risk of severe illness, contact your healthcare provider to see if you would benefit from early diagnostic testing. Treatments for influenza and COVID-19 are available that, if given within days of symptoms starting, can reduce your risk of hospitalization and death.

Distributed via the CDC Health Alert Network
September 05, 2023, 2:00 PM ET

Да, Questar, и аз съм така - не просто разочарована, а отвратена от хорското безхаберие спрямо самите тях и себеподобните, както и от безхаберието на овластените институции и лъжите им..
И просто за информация:
Лекарство Merck Covid, свързано с вирусни мутации, които могат да се разпространяват между хората, се казва в ново проучване https://www.cnbc.com/2023/09/25/merck-covid-drug-linked-to-virus … -study-says-.html
Разбира се, новите мантри са, че нямало доказателства.То така нямаше и доказателства, че след масовата воксинация, вирусът ще мутира още по-зле..

Да, Questar, и аз съм така - не просто разочарована, а отвратена от хорското безхаберие спрямо самите тях и себеподобните, както и от безхаберието на овластените институции и лъжите им..
И просто за информация:
Лекарство Merck Covid, свързано с вирусни мутации, които могат да се разпространяват между хората, се казва в ново проучване https://www.cnbc.com/2023/09/25/merck-covid-drug-linked-to-virus … -study-says-.html
Разбира се, новите мантри са, че нямало доказателства.То така нямаше и доказателства, че след масовата воксинация, вирусът ще мутира още по-зле..